Trial reportAntimicrobial agents and chemotherapy2009
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
Trial report in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 80 citations in OpenAlex.
- Challenging the Concept of Uncomplicated Candidemia for Shorter Courses of Antifungal Therapy.Open forum infectious diseases · 2026Article
- Evaluation of Candida Species Colonization and Fungal Susceptibility Profile in the Oropharyngeal Mucosa of Patients Receiving Head and Neck Radiotherapy.TheScientificWorldJournal · 2026Article
- Oral Candida carriage and resistance against common antifungal agents in hematopoietic stem cell transplantation recipients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors.Journal of fungi (Basel, Switzerland) · 2023Article
- Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome.Transplantation and cellular therapy · 2022Article
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Prognostic factors ofLancet regional health. Americas · 2022Article
- Molecular identification and antifungal susceptibility testing ofCurrent medical mycology · 2021Article
- Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria.Computational and structural biotechnology journal · 2021Review
- Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity.Blood advances · 2020Article
- Upregulation of secreted aspartyl proteinase genes of fluconazole-sensitive Candida albicans isolates.Molecular biology reports · 2019Article
- Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.Infection · 2019Article
- Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistantJournal of oral microbiology · 2018Article
- What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.The Journal of antimicrobial chemotherapy · 2018Review
- Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment.Infection and drug resistance · 2018Article
- Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis.Cancer medicine · 2017Review
- Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.Medical mycology · 2017Article
- Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients.Antimicrobial agents and chemotherapy · 2017Article
- Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Antimicrobial agents and chemotherapy · 2015Article
- Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol.Journal of clinical microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two large studies compared posaconazole and fluconazole or itraconazole for prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation or subjects with acute myelogenous leukemia. To assess the impact of prophylaxis on colonization and the development of resistance in Saccharomyces yeasts, identification and susceptibility testing were performed with yeasts cultured at regular intervals from mouth, throat, and stool samples. Prior to therapy, 34 to 50% of the subjects were colonized with yeasts. For all three drugs, the number of positive Candida albicans cultures decreased during drug therapy. In contrast, the proportion of subjects with positive C. glabrata cultures increased by two- and fourfold in the posaconazole and itraconazole arms, respectively. Likewise, in the fluconazole arm the proportion of subjects with positive C. krusei cultures increased twofold. C. glabrata was the species that most frequently exhibited decreases in susceptibility, and this trend did not differ significantly between the prophylactic regimens. For the subset of subjects from whom colonizing C. glabrata isolates were recovered at the baseline and the end of treatment, approximately 40% of the isolates exhibited more than fourfold increases in MICs during therapy. Molecular typing of the C. albicans and C. glabrata isolates confirmed that the majority of the baseline and end-of-treatment isolates were closely related, suggesting that they were persistent colonizers and not newly acquired. Overall breakthrough infections by Candida species were very rare (approximately 1%), and C. glabrata was the colonizing species that was the most frequently associated with breakthrough infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.